Overview

Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).
Phase:
Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Sertraline